Insider · CIK 0001612528

Coats Lonnel

CIK 0001612528 Name as filed on the most recent filing

Filed as Coats Lonnel (12)

53 transaction lines · from 12 filings · filed 2017-09-18 to 2024-11-22 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

53 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2024-11-21 S, Open-market sale Blueprint Medicines CorpBPMC 932,003, disposed Open Form 4 filing 0001415889-24-027545
2024-11-20 S, Open-market sale Blueprint Medicines CorpBPMC 3 lines 937,655, disposed Open Form 4 filing 0001415889-24-027545
2023-11-16 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 94,797, acquired Open Form 4 filing 0001127602-23-027850
2023-11-10 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 10,100, acquired Open Form 4 filing 0001127602-23-027279
2023-06-29 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 21,600, acquired Open Form 4 filing 0001127602-23-019560
2023-06-26 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 21,792, acquired Open Form 4 filing 0001127602-23-019405
2023-06-23 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 24,950, acquired Open Form 4 filing 0001127602-23-019405
2023-06-22 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 92,400, acquired Open Form 4 filing 0001127602-23-019231
2019-09-18 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 155,000, acquired Open Form 4 filing 0001127602-19-028814
2019-09-17 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 5 lines 156,403, acquired Open Form 4 filing 0001127602-19-028744
2019-08-19 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 4,194, acquired Open Form 4 filing 0001127602-19-027072
2019-08-16 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 7 lines 49,835, acquired Open Form 4 filing 0001127602-19-027072
2019-08-15 S, Open-market sale Blueprint Medicines CorpBPMC 3 lines 824,007, disposed Open Form 4 filing 0001179110-19-009616
2017-11-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 99,100, acquired Open Form 4 filing 0001127602-17-032220
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 65,208, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 53,290, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 41,316, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 40,706, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 30,120, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 25,140, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 24,505, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 15,092, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 15,023, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 7,570, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 7,510, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 5,054, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 5,014, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 5,006, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,836, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,794, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,787, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,785, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,773, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,765, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,746, acquired Open Form 4 filing 0001127602-17-027540
2017-09-15 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 3,746, acquired Open Form 4 filing 0001127602-17-027540

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 46
  • Open-market sale 7
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. COATS LONNEL, insider transactions. Retrieved 2026-08-26 from https://ebomi.com/insider/0001612528

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.